VIR Wichtige Statistiken
Hoch
9.09
Öffnen
8.82
Volumen
1.68M
Niedrig
8.77
Vorheriger Schlusskurs
8.69
Handelswert
14.99M
52W-Hoch
11.66
Rel. Volumen
1.022
Amplitude (%)
3.62%
52W-Tief
4.16
Umsatzrate
1.00%
Marktkapitalisierung
1.46B
KGV (TTM)
--
KGV (Jährlich)
2.234
KBV
1.8
KUV
22.38
Gewinn je Aktie (EPS)
-3.137
Dividende (TTM)
0
Dividendenrendite
0.00%
Ausstehende Aktien
168.65M
Währung
USD
VIR Preis-Performance
7 Tag
30 Tag
90 Tag
180 Tag
Seit Jahresbeginn
1 Jahr
VIR Moneyflow-Verteilung
VIR Tägliches Leerverkaufsvolumen
VIR Short-Interest-Historie
VIR Aktien-Snapshot
As of 2026-07-28, the Vir Biotechnology, Inc. (VIR) stock price today is 8.8. Based on this price, the company has a market capitalization of $1.46B, with a P/E ratio of --.
On 2026-07-28, VIR traded between 8.77 and 9.09. Today’s stock price is 0.34% above the daily low and 3.19% below the daily high, placing VIR nahe dem unteren Ende von its most recent trading range.
Trading volume currently stands at 1.68M, compared with an average daily volume of 1.65M. This suggests that trading activity is ungefähr im Einklang mit dem üblichen Niveau than usual.
Over the past year, Vir Biotechnology, Inc. shares have traded between 4.16 and 11.66. At today’s price, VIR is 111.54% above its 52-week low and 24.53% below its 52-week high.
VIR Verwandte Nachrichten
Über VIR
Firmenname
Vir Biotechnology, Inc.
Sektor
Health Technology
Branche
Biotechnology
Börsen
Nasdaq
Anzahl der Beschäftigten
367
Losgröße
100
Offizielle Website
Währung
USD
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Related Stocks
VIR FAQ
© 2026 CoinGlass, all rights reserved
